Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Cost Plus Drugs vs Medro

Cost Plus Drugs
Graded #370

Lower grade

vs+5.100000000000001
Medro
Graded #252

Higher grade

The verdict

Medro takes it — 63.6/100 to 58.5/100.

Medro grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Medro (Medro Health Technologies, Inc.) is a telehealth brand whose GLP-1 program offers compounded semaglutide and tirzepatide, plus brand-name GLP-1s when eligible, via a partner medical group and…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedro +5
45
50
Dose & formulationMedro +12
65
77
Clinical oversightMedro +4
67
71
Labs & monitoringMedro +1
51
52
FulfillmentMedro +19
73
92
Contract termsCost Plus Drugs +22
55
33
Cost Plus Drugs · left barMedro · right bar

The numbers

MetricCost Plus DrugsMedro
WeighScore58.5/10063.6/100
GradeCC
Scorecard rank#370#252
Semaglutide$279/mo (brand Ozempic)$199/mo (compounded)
TirzepatideNot disclosed$299/mo (compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Cost Plus Drugs

Graded #370 · C

Strengths

  • Transparent pricing: wholesale cost + 15% markup + $5 pharmacy fee, the same for everyone
  • Around $279/mo for branded Ozempic — well below typical retail list prices
  • Mark Cuban's PBM-disrupting pharmacy, praised by Forbes Health, Wired, and KFF Health News
  • Ships to all 50 states; genuine FDA-approved Novo Nordisk Ozempic, not compounded
  • Partnered with 9amHealth so you can get prescribed and fill at Cost Plus pricing

Where it loses points

  • Fulfillment only — no telehealth intake; you need a prescription from an outside clinician
  • Ozempic is FDA-indicated for type 2 diabetes, not weight management — weight-loss use is off-label
  • Wegovy availability has been spotty — check current stock before assuming it ships
  • No compounded semaglutide or tirzepatide — brand only
  • No clinical follow-up — side-effect monitoring falls to your prescribing clinician
Medro

Graded #252 · C

Strengths

  • Covers both compounded semaglutide and tirzepatide and can prescribe brand-name GLP-1s when clinically appropriate.
  • LegitScript-certified (seal #50716646), available in all 50 states, with tiered pricing shown before checkout.
  • No membership fee and free expedited shipping on all orders; online intake with no appointment required in many cases.
  • Prices drop with longer commitments (semaglutide to $149/mo, tirzepatide to $224/mo on a 12-month plan).

Where it loses points

  • Does not name its compounding pharmacy or its clinical partner medical group, so the fulfillment chain is not verifiable.
  • Pricing is described as illustrative and may change by dose, pharmacy availability, and eligibility — final cost shows only at checkout.
  • Very new brand (2026, trademark pending) spanning many verticals, with a short track record in GLP-1 care.
  • Compounded medications are not FDA-approved or therapeutically equivalent to Ozempic, Wegovy, Mounjaro, or Zepbound.

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard